Company Analysis
Sign in

Immuron Limited (IMRN)

Nasdaq: IMRN · Pharmaceutical Preparations · Carlton, Victoria, AU · filing with the SEC since 2016
Full chart Alerts Compare
Grade6.0
◀ Past 6.5● Present 6.3▶ Future 5.5
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
RevenueA$7.3M+48.6%
Net income-A$5.2M+24.8%
Earnings per sharen/a
Operating cash flow-A$6.1M-4.4%
CashA$2.8M-75.7%
Debtn/a
Shareholders’ equityA$8.1M-36.5%
Shares, diluted230.9M+1.4%
Return on equity-64.6%
The recordfrom its filings
Filings in 202645
Newest filingNov 10 · 6-K
Annual reportSep 24, 2026
Quarterly reportn/a
Next report due20-F by Oct 28
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted5
Filer categoryNon-accelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
16171819202122232425
As filed, in AUD. Nothing here is a forecast.

News

Oct 23, 2026 · SEC EDGAR · Form 424B5
Shelf offering
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton IMRN · research, not advice